Aventis To Pay $96M To End Medicaid Rebate Probe
Aventis Pharmaceutical Inc. has agreed to pay $95.5 million to settle allegations that the drugmaker violated federal law by misreporting nasal spray prices in order to reduce its Medicaid rebate obligations....To view the full article, register now.
Already a subscriber? Click here to view full article